Cochrane for Clinicians: Putting Evidence into Practice
Does Long-Term Anticoagulation Improve Function After Stroke?
FREE PREVIEW. AAFP members and paid subscribers: Log in to get free access. All others: Purchase online access.
FREE PREVIEW. Purchase online access to read the full version of this article.
Am Fam Physician. 2003 Jun 1;67(11):2317-2318.
A 70-year-old man with normal sinus rhythm had a thrombotic stroke that resulted in weakness in his non-dominant hand and leg.
Should this patient receive long-term anticoagulation to improve function or reduce the possibility of recurrent vascular events and death?
There is no evidence that anticoagulation with either heparin or warfarin improves these outcomes. There is clear evidence of increased hemorrhagic complications (both fatal and nonfatal) in patients who receive anticoagulation.
Background. After a first ischemic stroke, further vascular events resulting from thromboembolism (especially myocardial infarction and recurrent stroke) are common and often fatal. Anticoagulants potentially could reduce the risk of such events, but any benefits could be offset by an increased risk of fatal or disabling hemorrhages.
Objectives. The objective of this review1 was to assess the effect of prolonged anticoagulant therapy (compared with placebo or open control) following presumed non-cardioembolic ischemic stroke or transient ischemic attack.
Search Strategy. The authors searched the Cochrane Stroke Group trials register. They contacted companies marketing anticoagulant agents. The most recent search for this review was carried out in August 2002.
Selection Criteria. Randomized and quasi-randomized trials comparing at least one month of anticoagulant therapy with control in persons with previous presumed non-cardioembolic ischemic stroke or transient ischemic attack were included.
Data Collection and Analysis. Two reviewers independently selected trials for inclusion, assessed trial quality, and extracted the data.
Primary Results. Eleven trials involving 2,487 patients were included. The quality of the nine trials that predated routine computerized tomo-graphic scanning and use of the International Normalized Ratio to monitor anticoagulation was poor. There was no evidence of an effect of anticoagulant therapy on the odds of death or dependency (two trials, odds ratio [OR], 0.83; 95 percent confidence interval [CI], 0.52 to 1.34) or of “nonfatal stroke, myocardial infarction, or vascular death” (four trials, OR, 0.96; 95 percent CI, 0.68 to 1.37). Death from any cause (OR, 0.95; 95 percent CI, 0.73 to 1.24) and death from vascular causes (OR, 0.86; 95 percent CI, 0.66 to 1.13) were not significantly different between treatment and control groups. The inclusion of two recently completed trials did not alter these conclusions. There was no evidence of an effect of anticoagulant therapy on the risk of recurrent ischemic stroke (OR, 0.85; 95 percent CI, 0.66 to 1.09). However, anticoagulants increased fatal intracranial hemorrhage (OR, 2.54; 95 percent CI, 1.19 to 5.45), and major extracranial hemorrhage (OR, 3.43; 95 percent CI, 1.94 to 6.08). This is equivalent to anticoagulant therapy causing about 11 additional fatal intracranial hemorrhages and 25 additional major extracranial hemorrhages per year for every 1,000 patients given anticoagulant therapy.
Reviewers' Conclusions. Compared with control, there was no evidence of benefit from long-term anticoagulant therapy in persons with presumed non-cardioembolic ischemic stroke or transient ischemic attack, but there was a significant bleeding risk.
These summaries have been derived from Cochrane reviews published in the Cochrane Database of Systematic Reviews in the Cochrane Library. Their content has, as far as possible, been checked with the authors of the original reviews, but the summaries should not be regarded as an official product of the Cochrane Collaboration; minor editing changes have been made to the text (http://www.cochrane.org).
Did the author address a focused clinical question? Yes. Several other reviews in the Cochrane Stroke Group address specific issues such as acute anticoagulation, anticoagulant versus antiplatelet therapy, and anticoagulation in atrial fibrillation.
Were the criteria used to select articles for inclusion appropriate? Yes.
Is it likely that important relevant articles were missed? No. A search for unpublished articles, including those by relevant pharmaceutical manufacturers, was conducted.
Was the validity of the individual articles appraised? Yes.
Were the assessments of studies reproducible? Yes.
Were the results similar from study to study? Yes.
How precise were the results? The results on hemorrhage, recurrent stroke, and death are robust. Other end points, such as recurrent vascular events and function, are more difficult to base conclusions on because of the differing definitions and methods of the included trials.
Can the results be applied to patient care? Yes.
Do the conclusions make clinical and biologic sense? Yes.
Are the benefits worth the harms and costs? The review recommends against this intervention, so no extra cost is involved. There are significant cost savings.
There are about 4.6 million stroke survivors in the United States today, and 600,000 people have new strokes each year. These patients are at increased risk of recurrent stroke, other vascular events, dependency, and death.2 Patients whose strokes had a cardioembolic source (e.g., atrial fibrillation) generally should receive anticoagulation for secondary prevention, but the appropriate treatment is more controversial in patients with thrombotic strokes. One survey3 noted that 53 percent of randomly selected U.S. physicians always or often prescribe an anticoagulant for patients with transient ischemic attack or recent minor stroke.
This review shows that there is no convincing evidence that prolonged anticoagulation is beneficial following presumed noncardioembolic stroke or transient ischemic attack. There is, however, convincing evidence that anticoagulation increases the rate of fatal intracranial hemorrhages and major extracranial hemorrhages. A separate Cochrane review4 and a recent joint American Heart Association/American Academy of Neurology committee5 found no evidence of benefit from anticoagulation within 48 hours from the onset of stroke. A third Cochrane review6 found no additional benefit from adding anticoagulant therapy to antiplatelet therapy.
Anticoagulant therapy has a narrow therapeutic window and is a difficult regimen to manage in a consistently safe manner. This is especially true in elderly patients, who have a higher rate of hemorrhagic complications and who often are on complex medical regimens with increased risk of drug-drug interactions. Although as physicians we want to be able to intervene to reduce the suffering of patients with stroke, the best course is to use antiplatelet therapy instead of anticoagulation.
REFERENCESshow all references
1. Sandercock P, Mielke O, Liu M, Counsell C. Anticoagulants for preventing recurrence following presumed non-cardioembolic ischaemic stroke or transient ischaemic attack. Cochrane Database Syst Rev. 2003:CD000248....
2. American Heart Association. 2002 heart and stroke statistical update. Dallas, Tex.: The Association, 2001.
3. Goldstein LB, Farmer A, Matchar DB. Primary care physician-reported secondary and tertiary stroke prevention practices. A comparison between the United States and the United Kingdom. Stroke. 1997;28:746–51.
4. Gubitz G, Counsell C, Sandercock P, Signorini D. Anticoagulants for acute ischaemic stroke. Cochrane Database Syst Rev. 2003:CD000024.
5. Coull BM, Williams LS, Goldstein LB, Meschia JF, Heitzman D, Chaturvedi S, et al. Anticoagulants and antiplatelet agents in acute ischemic stroke: report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a division of the American Heart Association). Stroke. 2002;33:1934–42.
6. Berge E, Sandercock P. Anticoagulants versus antiplatelet agents for acute ischaemic stroke. Cochrane Database Syst Rev. 2003:CD003242.
The Cochrane Abstract is a summary of a review from the Cochrane Library. It is accompanied by an interpretation to help clinicians put evidence into practice. Dan Brewer, M.D., presents a clinical scenario and question based on the Cochrane Abstract, along with an evidence-based answer and a full critique of the abstract
Copyright © 2003 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact email@example.com for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions